PALO ALTO, Calif. & ROCHESTER, Minn.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the largest study to date evaluating circulating tumor DNA (ctDNA) for MRD detection in patients with resected stage III colon cancer after surgery and before adjuvant chemotherapy. Results of the study, published in the Journal of Clinical Oncology, show that d ...

This genomics stock appears to be at an inflection point.Guardant Health (GH +0.68%) is on the rise, in more ways than one. Shares of the precision oncology company have skyrocketed over the last six months. Guardant Health has also chalked up several key victories recently, including signing a multi-year collaboration with Merck (MRK +1.35%) to develop companion diagnostics and market new cancer therapies with Guardant's Infinity Smart program. Although Guardant Health hasn't announced a date for releasing ...

Guardant Health, Inc. ( GH ) was founded in 2012 and is based in Palo Alto, CA. It describes itself as a "precision oncology company focused on guarding wellness and giving every person more time free from cancer." TheI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the key to creat ...

Core Insights - The FDA approved Guardant Health's Guardant360 CDx as a companion diagnostic for identifying patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from Braftovi treatment [1][4] - The approval is based on data from Pfizer's Phase 3 BREAKWATER trial, showing significant improvements in treatment outcomes [2] Group 1: Product and Approval Details - Guardant360 CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling, detecting multiple genomic alterations across solid tumors [2] - The test aids in identifying patients eligible for FDA-approved treatments using a simple blood draw, which is crucial when tumor tissue is unavailable [3] - Colorectal cancer is the second-leading cause of cancer-related deaths in the U.S., with BRAF V600E mutations found in approximately 8-10% of metastatic colorectal cancer cases [4] Group 2: Financial Performance and Collaborations - Guardant Health reported preliminary fourth quarter 2025 revenues of $280 million, a 39% increase year over year, with 2025 sales reaching $981 million, up 33% [5] - The company entered a multi-year collaboration with Merck to support the development of Merck's oncology portfolio using the Guardant Infinity Smart platform [5] Group 3: Stock Performance and Market Sentiment - Guardant Health's stock is trading 10% above its 20-day simple moving average and 37.8% above its 100-day simple moving average, indicating strong short-term momentum [6] - Over the past 12 months, the stock has increased by 145.23% and is closer to its 52-week highs [6] - Analysts expect a loss of $(0.61) per share in the upcoming earnings report, with revenue projected at $273.83 million, up from $201.81 million a year ago [8] Group 4: Analyst Ratings and Market Position - The stock carries a Buy rating among analysts with an average price target of $87.25, reflecting positive sentiment ahead of the earnings release [9] - Guardant Health scores high on the Benzinga Edge, indicating strong momentum and outperforming the broader market [10]

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy in accordance with the approved product labeling. The accelerated approval was su. ...

Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The US equity market ended the fourth quarter on a strong note, with the S&P surging 2.7%, maintaining its steady upward momentum. Investors' optimism was supported by better-than-expected corporate earnings, the US Federal Reserve’s further interest rate easing stance, and a resilient macroeconomic backdrop. Improving clarity on ...

Core Insights - Guardant Health, Inc. is ranked fifth in a list of the Top 10 Oncology Stocks to Buy Now, indicating strong market interest and potential for growth [1] - Analysts from Stifel and Mizuho have raised their price targets for Guardant Health, with Stifel increasing it to $120 and Mizuho to $135, reflecting positive sentiment and expectations for future performance [2][3] Company Overview - Guardant Health, Inc. specializes in precision oncology, focusing on non-invasive liquid biopsy tests for cancer detection, treatment selection, and disease monitoring [3] - The company's flagship products, Guardant360 and Guardant Shield, facilitate early cancer detection, biomarker profiling, and real-time monitoring, which are essential for personalized cancer care [3] Market Expectations - Stifel anticipates strong volume and average selling price growth for Guardant Health in 2026, supported by publication and reimbursement events that are expected to maintain investor interest [1] - Mizuho has revised its models for the diagnostics and medical device sectors, indicating a broader positive outlook for the industry in which Guardant operates [2]

Core Points - Gamehost Inc. has declared a cash dividend of $0.05 (CDN) per common share for January 2026, which annualizes to $0.60 (CDN) per share [1] - The dividend will be paid on February 13, 2026, to shareholders of record on January 31, 2026 [1] - This dividend is classified as an "Eligible Dividend," allowing Canadian shareholders to benefit from enhanced gross-up and dividend tax credits [2] Company Overview - Gamehost Inc. is incorporated under the laws of Alberta, Canada, and operates various facilities within the province, including the Rivers Casino & Entertainment Centre, Great Northern Casino, Service Plus Inns & Suites, Encore Suites hotels, and Deerfoot Inn & Casino [3] - The company's common shares are traded on the Toronto Stock Exchange (TSX) under the symbol GH [4]

Core Points - Gamehost Inc. has had a temporary increase in slot commissions from 15% to 17%, effective from April 1, 2023, to March 31, 2025, which has now been extended for an additional three years until March 31, 2029, to promote investment in marketing and site improvements [1] - The Alberta Gaming, Liquor and Cannabis (AGLC) announcement also allows land-based casinos to partner with Play Alberta for retail sportsbook opportunities [1] Company Overview - Gamehost Inc. is incorporated under the laws of Alberta, Canada, and operates various facilities including the Rivers Casino & Entertainment Centre in Ft. McMurray, the Great Northern Casino, Service Plus Inns & Suites, Encore Suites hotels, and the Deerfoot Inn & Casino in Calgary [2] - The company's common shares are traded on the Toronto Stock Exchange (TSX) under the symbol GH [3]

Core Insights - Guardant Health, Inc. has announced a multi-year collaboration with Merck to support the development and commercialization of Merck's oncology portfolio using the Guardant Infinity Smart platform [1] - The collaboration aims to enhance the precision of oncology programs by ensuring that clinical trials have the necessary molecular clarity to identify the right patients for treatment [1] Company Overview - Guardant Health is a leading precision oncology company founded in 2012, focused on improving patient care and accelerating cancer therapies through advanced blood and tissue tests, real-world data, and AI analytics [2] - The company's tests are designed to improve outcomes across all stages of cancer care, including early screening, monitoring for recurrence, and treatment selection for advanced cancer patients [2] Collaboration Details - The collaboration includes using Guardant's portfolio of liquid and tissue biopsy tests as clinical trial enrolling assays in Merck's global clinical studies [4] - There will be an evaluation of opportunities to develop novel therapies using Guardant liquid biopsy tests as companion diagnostics [4] - The partnership will also focus on global commercialization of drugs and companion diagnostics in markets including the US, Asia-Pacific, UK, and EU [4]